Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass

Inclusion Criteria: * Healthy volunteers who have had a gastric bypass at least 6 months ago and whose body weight has not changed more than 5% during the last 3 months * Age between 18 and 60 years old * Able to give informed consent Exclusion Criteria: * Other forms of bariatric surgery (Scopinaro and Mason/Sleeve) before gastric bypass surgery * Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients * Pregnancy and lactation * Creatinine clearance \< 80 ml/min * Transaminases \> 2x the upper limit of normal (AST/ALT) * Impaired liver function (Child Pugh C) * Fasting glycaemia \> 125mg/dl * Epilepsy * Patients with a history of tendon disease/disorder (especially Achilles tendon rupture) related to quinolone treatment * Patients with the following heart disorders: * Electrolyte disturbance, particularly an uncorrected hypokalaemia * Clinically relevant bradycardia * Clinically relevant heart failure with reduced left-ventricular ejection fraction * Previous history of symptomatic arrhythmias * Congenital or documented acquired QT prolongation or concurrently use of drugs that prolong the QT interval: * anti-arrhythmics (Classes IA and III) * neuroleptics * tricyclic antidepressants * antimicrobials (e.g. sparfloxacin, intravenous erythromycin, pentamidine, antimalarials particularly halofantrine) * some antihistamines (e.g. terfenadine, astemizole, mizolastine) * cisapride, intravenous vincamine, bepridil and diphemanil * No normal thyroid function * All clinically significant disorders that can interfere with the study